Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine, Low-Dose Cytarabine, and Decitabine in Untreated AML or High-Risk MDS
NCT01515527Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2012
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cladribine, cytarabine, decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2012; status: recruiting.
02
Drugs
cladribinecytarabinedecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01515527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01515527.